{"entity":{"edinet_code":"E00984","sec_code":"4568","name_ja":"第一三共株式会社","name_en":"DAIICHI SANKYO COMPANY, LIMITED","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YZB3","filer_name":"第一三共株式会社","filer_name_en":"DAIICHI SANKYO COMPANY, LIMITED","period_end":"2026-03-31","filed_date":"2026-08-28","sha256":"bd850cf4c06585201804a8846ee474d1e3c216be3e02081d6875b192d960a06b","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"株式会社しずおかフィナンシャルグループ","held_name_en":"Shizuoka Financial Group, Inc.","held_sec_code":"5831","match_status":"matched","shares":5449000,"book_value_yen":13963000000,"prior_shares":6129000,"prior_book_value_yen":9947000000,"purpose_ja":"同社グループ会社と行っている金融取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":1.0263775276220672,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8291405215931041,"pct_of_holder_assets":0.34939950479007376,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"クオリプス株式会社","held_name_en":"Cuorips Inc.","held_sec_code":"4894","match_status":"matched","shares":1000000,"book_value_yen":7010000000,"prior_shares":1000000,"prior_book_value_yen":8310000000,"purpose_ja":"同社株式は、事業上の関係の維持強化のため保有しております。","reciprocal":"無","pct_outstanding":12.110091387593647,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.41626262668249375,"pct_of_holder_assets":0.17541291474456902,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Ultragenyx Pharmaceutical Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":1243913,"book_value_yen":4167000000,"prior_shares":1243913,"prior_book_value_yen":6735000000,"purpose_ja":"同社が保有する遺伝子治療薬製造技術を非独占的に利用する契約を締結しており、今後の事業上の関係を維持強化するため保有しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.24744170690241818,"pct_of_holder_assets":0.10427184247369745,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ＭＳ＆ＡＤインシュアランスグループホールディングス株式会社","held_name_en":"MS&AD Insurance Group Holdings, Inc.","held_sec_code":"8725","match_status":"matched","shares":659089,"book_value_yen":2657000000,"prior_shares":1294689,"prior_book_value_yen":4175000000,"purpose_ja":"同社グループ会社と行っている保険取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":0.04531625758730298,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.15777600557708785,"pct_of_holder_assets":0.0664867495686619,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"クオールホールディングス株式会社","held_name_en":"Qol Holdings Co.,Ltd.","held_sec_code":"3034","match_status":"matched","shares":1304000,"book_value_yen":2430000000,"prior_shares":1304000,"prior_book_value_yen":2358000000,"purpose_ja":"同社グループ会社と行っている医薬品販売等に関する取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"無","pct_outstanding":3.470153816430726,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1442964597487104,"pct_of_holder_assets":0.06080647401273933,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東京海上ホールディングス株式会社","held_name_en":"Tokio Marine Holdings, Inc.","held_sec_code":"8766","match_status":"matched","shares":229800,"book_value_yen":1679000000,"prior_shares":344700,"prior_book_value_yen":1977000000,"purpose_ja":"同社グループ会社と行っている保険取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":0.012222998555792616,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09970113412266862,"pct_of_holder_assets":0.0420140205215594,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業株式会社","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":313000,"book_value_yen":1455000000,"prior_shares":613000,"prior_book_value_yen":2356000000,"purpose_ja":"同社と行っている医薬品製造取引における取引関係の維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":0.7550886764803266,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08639973207175869,"pct_of_holder_assets":0.036408814686640215,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"株式会社いよぎんホールディングス","held_name_en":"Iyogin Holdings, Inc.","held_sec_code":"5830","match_status":"matched","shares":470000,"book_value_yen":1330000000,"prior_shares":470000,"prior_book_value_yen":826000000,"purpose_ja":"同社グループ会社と行っている金融取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":0.16225834282426685,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0789770746772777,"pct_of_holder_assets":0.033280909644832636,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"株式会社アインホールディングス","held_name_en":"AIN HOLDINGS INC.","held_sec_code":"9627","match_status":"matched","shares":114000,"book_value_yen":641000000,"prior_shares":114000,"prior_book_value_yen":574000000,"purpose_ja":"同社グループ会社と行っている医薬品販売等に関する取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"無","pct_outstanding":0.32262709469886325,"pct_unavailable":null,"pct_basis_period_end":"2026-04-30","pct_share_classes":1,"pct_of_holder_equity":0.0380633871188985,"pct_of_holder_assets":0.016039897054389265,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"株式会社ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":438500,"book_value_yen":403000000,"prior_shares":438500,"prior_book_value_yen":388000000,"purpose_ja":"同社グループ会社と行っている医薬品販売等に関する取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":2.1331763652815208,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0239306474398067,"pct_of_holder_assets":0.010084365854787634,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"第一生命ホールディングス株式会社","held_name_en":"Daiichi Life Group, Inc.","held_sec_code":"8750","match_status":"matched","shares":118400,"book_value_yen":168000000,"prior_shares":29600,"prior_book_value_yen":134000000,"purpose_ja":"同社グループ会社と行っている保険取引における取引関係の構築・維持・強化を目的として保有しております。なお、当事業年度中に株式分割が行われたことにより、株式数が増加しております。","reciprocal":"有","pct_outstanding":0.0032715939536963664,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.009976051538182446,"pct_of_holder_assets":0.004203904376189386,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["share split"],"note_refs":[],"share_ratio":4.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Silence Therapeutics PLC（上場）","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":48489,"book_value_yen":40000000,"prior_shares":48489,"prior_book_value_yen":20000000,"purpose_ja":"同社株式は、事業上の関係の維持強化のため保有しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.0023752503662339158,"pct_of_holder_assets":0.0010009296133784253,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Cardiogeni PLC","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":1485150,"book_value_yen":21000000,"prior_shares":1485150,"prior_book_value_yen":21000000,"purpose_ja":"同社株式は、事業上の関係の維持強化のため保有しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.0012470064422728058,"pct_of_holder_assets":0.0005254880470236732,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Coiled Therapeutics PLC","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":99478,"book_value_yen":1000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"同社株式は、事業上の関係の維持強化のため保有しております。従来、Roquefort Therapeutics PLC社株式を事業上の関係の維持・強化を目的として保有しておりました。当事業年度中に同社によるCoiled Therapeutics, Inc.の買収及び資本再構成に伴い新たな普通株式の割当を受けたことにより、保有株式数が増加しております。また、当該手続の完了に伴い、同社の商号はRoquefort Therapeutics PLCから現商号に変更されております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":5.93812591558479e-05,"pct_of_holder_assets":2.502324033446063e-05,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"株式会社みずほフィナンシャルグループ","held_name_en":"Mizuho Financial Group, Inc.","held_sec_code":"8411","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":475536,"prior_book_value_yen":1926000000,"purpose_ja":"同社グループ会社と行っている金融取引における取引関係の構築・維持・強化を目的として保有しておりましたが、当事業年度中に全て売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"株式会社レナサイエンス","held_name_en":"Renascience Inc.","held_sec_code":"4889","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":30000,"prior_book_value_yen":31000000,"purpose_ja":"同社とは独占的実施許諾（ライセンス）に関する優先交渉権を得るオプション契約を締結しておりましたが、2025年４月の契約終了に伴い、当事業年度中に全て売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"株式会社三井住友フィナンシャルグループ","held_name_en":"Sumitomo Mitsui Financial Group, Inc.","held_sec_code":"8316","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":1139100,"prior_book_value_yen":4322000000,"purpose_ja":"同社グループ会社と行っている金融取引における取引関係の構築・維持・強化を目的として保有しておりましたが、当事業年度中に全て売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"株式会社静岡銀行","holder_name_en":"THE SHIZUOKA BANK, LTD.","holder_sec_code":"8355","doc_id":"S100O98X","period_end":"2022-03-31","holder_table":"reporting","shares":32922790,"book_value_yen":88233000000,"prior_shares":34172790,"prior_book_value_yen":110207000000,"purpose_ja":"(保有目的)発行会社グループとの総合的な取引の維持・拡大(定量的な保有効果)保有に関する資本コスト等を算出し検証済","reciprocal":"有","pct_outstanding":1.7176033690708392,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":8.107810083556398,"pct_of_holder_assets":0.5914442781974024,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1088247000000,"holder_total_assets_yen":14918227000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社しずおかフィナンシャルグループ","holder_name_en":"Shizuoka Financial Group, Inc.","holder_sec_code":"5831","doc_id":"S100Y9RT","period_end":"2026-03-31","holder_table":"largest","shares":22422790,"book_value_yen":62021000000,"prior_shares":22422790,"prior_book_value_yen":78726000000,"purpose_ja":"(保有目的)静岡県内外において創薬を含む国内医薬品事業を通じて当社グループの営業基盤である地域の生産・消費活動や雇用創出を支える重要な大手医薬品製造業者であり、同社グループとの銀行取引をはじめとした総合的な取引の維持・拡大といった便益に加えて、当該取引を含む連携を通じ地域産業や地域雇用の観点から地域経済活性化を促進する間接的な効果も見据え、当社グループの中長期的な企業価値の向上を図ることを目的に保有しています (定量的な保有効果)保有に関する資本コスト等を算出し検証済","reciprocal":"有","pct_outstanding":1.2227318716511435,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":5.034580728955272,"pct_of_holder_assets":0.3872436433157686,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1231900000000,"holder_total_assets_yen":16016015000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社伊予銀行","holder_name_en":"The Iyo Bank, Ltd.","holder_sec_code":"8385","doc_id":"S100OLYJ","period_end":"2022-03-31","holder_table":"reporting","shares":8968824,"book_value_yen":24036000000,"prior_shares":8968824,"prior_book_value_yen":28924000000,"purpose_ja":"緊密な関係の維持強化","reciprocal":"有","pct_outstanding":0.46790938189027725,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":3.284512939363048,"pct_of_holder_assets":0.2812939850999386,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":731798000000,"holder_total_assets_yen":8544797000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社いよぎんホールディングス","holder_name_en":"Iyogin Holdings, Inc.","holder_sec_code":"5830","doc_id":"S100YBIB","period_end":"2026-03-31","holder_table":"largest","shares":7787824,"book_value_yen":21541000000,"prior_shares":7787824,"prior_book_value_yen":27343000000,"purpose_ja":"業界内での有力企業であり、総合的な関係の維持強化を図ることにより当社グループの中長期的な企業価値の向上に資するため保有しております。","reciprocal":"有","pct_outstanding":0.424675993291187,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.4537466310962066,"pct_of_holder_assets":0.2258010954513569,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":877882000000,"holder_total_assets_yen":9539812000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"largest","shares":6406200,"book_value_yen":21447000000,"prior_shares":6406200,"prior_book_value_yen":27879000000,"purpose_ja":"当社グループ会社において受託事業の取引があり、事業上の関係の維持・強化を目的として保有しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.34933498089093973,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7070181615352056,"pct_of_holder_assets":0.5109394453256438,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ＭＳ＆ＡＤインシュアランスグループホールディングス株式会社","holder_name_en":"MS&AD Insurance Group Holdings, Inc.","holder_sec_code":"8725","doc_id":"S100YNCJ","period_end":"2026-03-31","holder_table":"second_largest","shares":6040191,"book_value_yen":16707000000,"prior_shares":12080191,"prior_book_value_yen":42413000000,"purpose_ja":"保険取引先との関係の維持・強化を目的として安定保有していたが、保有方針については③a.(a)に記載のとおり","reciprocal":"有","pct_outstanding":0.32937623045840375,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.346249020753802,"pct_of_holder_assets":0.05833283724642612,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":4825140000000,"holder_total_assets_yen":28640815000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東京海上ホールディングス株式会社","holder_name_en":"Tokio Marine Holdings, Inc.","holder_sec_code":"8766","doc_id":"S100YLS8","period_end":"2026-03-31","holder_table":"largest","shares":3918300,"book_value_yen":10838000000,"prior_shares":5877400,"prior_book_value_yen":20635000000,"purpose_ja":"保険事業における顧客企業との長期的かつ安定的な保険取引関係の維持および強化を図り、当社グループの企業価値を高めることを目的として、保有してきたものです。現在は、当社グループのリスクポートフォリオを見直し、社会課題解決や成長分野等に対して資本を振り向けるため、売却方針に則り保有をゼロにすることをめざしています。","reciprocal":"有","pct_outstanding":0.21366789292013505,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1985865140371055,"pct_of_holder_assets":0.03390908061275379,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":5457571000000,"holder_total_assets_yen":31961940000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ＭＳ＆ＡＤインシュアランスグループホールディングス株式会社","holder_name_en":"MS&AD Insurance Group Holdings, Inc.","holder_sec_code":"8725","doc_id":"S100YNCJ","period_end":"2026-03-31","holder_table":"largest","shares":2400000,"book_value_yen":6638000000,"prior_shares":4500000,"prior_book_value_yen":15799000000,"purpose_ja":"保険取引先との関係の維持・強化を目的として安定保有していたが、保有方針については②a.(a)に記載のとおり","reciprocal":"有","pct_outstanding":0.1308738338076013,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.13757113783227015,"pct_of_holder_assets":0.023176714768766184,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":4825140000000,"holder_total_assets_yen":28640815000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":1285089,"book_value_yen":3554000000,"prior_shares":2570089,"prior_book_value_yen":9023000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.0700768850891569,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4468197722149512,"pct_of_holder_assets":0.18491135805269712,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ＳＯＭＰＯホールディングス株式会社","holder_name_en":"Sompo Holdings, Inc.","holder_sec_code":"8630","doc_id":"S100YC6Z","period_end":"2026-03-31","holder_table":"largest","shares":1096647,"book_value_yen":3033000000,"prior_shares":1096647,"prior_book_value_yen":3850000000,"purpose_ja":"上記①イ.保有目的Ａ","reciprocal":"無","pct_outstanding":0.05980099884316856,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.058690090585532824,"pct_of_holder_assets":0.016303204996166356,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":5167823000000,"holder_total_assets_yen":18603704000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社日立製作所","holder_name_en":"Hitachi, Ltd.","holder_sec_code":"6501","doc_id":"S100YGBO","period_end":"2026-03-31","holder_table":"reporting","shares":900000,"book_value_yen":2489000000,"prior_shares":900000,"prior_book_value_yen":3159000000,"purpose_ja":"インダストリアルデジタル事業における製品・サービスの販売・提供に係る取引関係を維持・強化するため、保有しています。","reciprocal":"無","pct_outstanding":0.049077687677850486,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.036750988208824165,"pct_of_holder_assets":0.016547831210260107,"holder_equity_basis":"ifrs_consolidated","holder_equity_yen":6772607000000,"holder_total_assets_yen":15041246000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"不二硝子株式会社","holder_name_en":"FUJI GLASS CO., LTD.","holder_sec_code":"5212","doc_id":"S100R1Z3","period_end":"2023-03-31","holder_table":"reporting","shares":308430,"book_value_yen":1487249000,"prior_shares":308430,"prior_book_value_yen":826592000,"purpose_ja":"主要販売先との取引関係の維持、強化のため","reciprocal":"無","pct_outstanding":0.016086315831759155,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":42.1898212750313,"pct_of_holder_assets":30.441275470343353,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":3525137000,"holder_total_assets_yen":4885633000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":524900,"book_value_yen":1451000000,"prior_shares":524900,"prior_book_value_yen":1842000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.02862319806900413,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5343202238915893,"pct_of_holder_assets":0.19587435422884766,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社青森銀行","holder_name_en":"The Aomori Bank，Ltd.","holder_sec_code":null,"doc_id":"S100OESC","period_end":"2022-03-31","holder_table":"reporting","shares":498900,"book_value_yen":1337000000,"prior_shares":997800,"prior_book_value_yen":3217000000,"purpose_ja":"同社の事業は今後も成長が見込まれる分野であり、関係を維持・強化することが、当行の企業価値向上に繋がるため ","reciprocal":"有","pct_outstanding":0.026027937511658085,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":1.1519506479183899,"pct_of_holder_assets":0.034646209595833956,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":116064000000,"holder_total_assets_yen":3859008000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":385974,"book_value_yen":1067000000,"prior_shares":385974,"prior_book_value_yen":1355000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.02104745713752296,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8988517947551534,"pct_of_holder_assets":0.3328466971126251,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":314000,"book_value_yen":868000000,"prior_shares":1214000,"prior_book_value_yen":4262000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、泌尿器科用薬剤の受託製造を行っています。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。株式数が減少した理由は、当事業年度において一部売却したことによるものです。","reciprocal":"有","pct_outstanding":0.01712265992316117,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3748877064473775,"pct_of_holder_assets":0.31553768639625424,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ほくやく・竹山ホールディングス","holder_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","holder_sec_code":"3055","doc_id":"S100YJPG","period_end":"2026-03-31","holder_table":"reporting","shares":216342,"book_value_yen":598000000,"prior_shares":216342,"prior_book_value_yen":759000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.0117972945640017,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.924794704854399,"pct_of_holder_assets":0.38410893791951695,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ダイト株式会社","holder_name_en":"Daito Pharmaceutical Co.,Ltd.","holder_sec_code":"4577","doc_id":"S100YYNI","period_end":"2026-05-31","holder_table":"reporting","shares":88500,"book_value_yen":238000000,"prior_shares":88500,"prior_book_value_yen":340000000,"purpose_ja":"(保有目的) 当社の製剤販売先であり、取引関係の維持・強化を目的として保有しております。","reciprocal":"無","pct_outstanding":0.004825972621655298,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.449582530507386,"pct_of_holder_assets":0.32473291400035476,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52938000000,"holder_total_assets_yen":73291000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ウエルシアホールディングス株式会社","holder_name_en":"WELCIA HOLDINGS CO., LTD.","holder_sec_code":"3141","doc_id":"S100VTBM","period_end":"2025-02-28","holder_table":"largest","shares":66000,"book_value_yen":227000000,"prior_shares":66000,"prior_book_value_yen":328000000,"purpose_ja":"取引関係の維持・強化のため保有しておりますが、今後の売却を予定しております。","reciprocal":"無","pct_outstanding":0.0035309141422387538,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08919940586122616,"pct_of_holder_assets":0.03913894324853229,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":254486000000,"holder_total_assets_yen":579985000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社マツキヨココカラ＆カンパニー","holder_name_en":"MatsukiyoCocokara&Co.","holder_sec_code":"3088","doc_id":"S100YD1I","period_end":"2026-03-31","holder_table":"reporting","shares":28017,"book_value_yen":77000000,"prior_shares":28017,"prior_book_value_yen":98000000,"purpose_ja":"（保有目的）商品の安定供給（商品仕入）を通じた当社事業の円滑化のため保有（定量的な保有効果）（注）２ ","reciprocal":"無　※２","pct_outstanding":0.0015277884174114856,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.014142686853362377,"pct_of_holder_assets":0.010187462541229455,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":544451000000,"holder_total_assets_yen":755831000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":8277,"book_value_yen":28000000,"prior_shares":8277,"prior_book_value_yen":41000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.0004428087326562146,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.010021223519811601,"pct_of_holder_assets":0.0081616472536057,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ソーダニッカ株式会社","holder_name_en":"SODA NIKKA CO., LTD.","holder_sec_code":"8158","doc_id":"S100YFPG","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":180505,"prior_book_value_yen":633000000,"purpose_ja":"(保有目的)販売先企業との関係強化のため。(定量的な保有効果)(注)","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":33774000000,"holder_total_assets_yen":77826000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"second_largest","shares":null,"book_value_yen":null,"prior_shares":236040,"prior_book_value_yen":828000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":null,"book_value_yen":null,"prior_shares":1631401,"prior_book_value_yen":5727000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社三井住友フィナンシャルグループ","holder_name_en":"Sumitomo Mitsui Financial Group, Inc.","holder_sec_code":"8316","doc_id":"S100YERK","period_end":"2026-03-31","holder_table":"largest","shares":null,"book_value_yen":null,"prior_shares":4697300,"prior_book_value_yen":16492000000,"purpose_ja":"主に預金・融資・為替等の金融関連の取引関係の維持・強化のため保有しておりました。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":15933144000000,"holder_total_assets_yen":328511145000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"（注）１．「－」は、当該銘柄を保有していないことを示しております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２．定量的な保有効果及び一部の業務提携等の概要については、取引先との営業秘密等との判断により記載いたしませんが、一定の経営指標、資本コスト等を踏まえて収益性、採算性を個別銘柄ごとに検証するとともに、事業戦略、事業上の関係を総合的に勘案して、保有の合理性を検証しております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":7,"sale_proceeds_yen":13528000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":1,"sale_proceeds_yen":15000000,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":39001000000,"listed_yen":35972000000,"unlisted_yen":3029000000,"listed_issues":14,"unlisted_issues":24,"equity_yen":1684033000000,"equity_basis":"ifrs_consolidated_excl_nci","total_assets_yen":3996285000000,"assets_basis":"ifrs_consolidated","pct_of_equity":2.315928488337224,"pct_of_assets":0.975931396284299,"equity_basis_label":"Consolidated equity attributable to owners of the parent (IFRS)","assets_basis_label":"Consolidated total equity (IFRS)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":35972000000,"issue_count":14,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":3029000000,"issue_count":24,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2020","period_end":"2020-03-31","policy_total_yen":49575000000,"equity_yen":1305809000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.7964970374687264,"pct_of_assets":2.3544145450815175},{"year":"2022","period_end":"2022-03-31","policy_total_yen":52232000000,"equity_yen":1350872000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.8665395389052404,"pct_of_assets":2.3513078677339805},{"year":"2023","period_end":"2023-03-31","policy_total_yen":47988000000,"equity_yen":1445854000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.3190073133248585,"pct_of_assets":1.912719135840605},{"year":"2024","period_end":"2024-03-31","policy_total_yen":59351000000,"equity_yen":1688173000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.515694185370812,"pct_of_assets":1.7147843120825972},{"year":"2025","period_end":"2025-03-31","policy_total_yen":47473000000,"equity_yen":1623416000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":2.9242658690070815,"pct_of_assets":1.3735927495552092},{"year":"2026","period_end":"2026-03-31","policy_total_yen":39001000000,"equity_yen":1684033000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":2.315928488337224,"pct_of_assets":0.975931396284299}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2019","period_end":"2019-03-31","named_holdings":32,"book_value_yen":73834000000},{"year":"2020","period_end":"2020-03-31","named_holdings":29,"book_value_yen":45314000000},{"year":"2022","period_end":"2022-03-31","named_holdings":23,"book_value_yen":48978000000},{"year":"2023","period_end":"2023-03-31","named_holdings":22,"book_value_yen":44797000000},{"year":"2024","period_end":"2024-03-31","named_holdings":21,"book_value_yen":54957000000},{"year":"2025","period_end":"2025-03-31","named_holdings":22,"book_value_yen":44103000000},{"year":"2026","period_end":"2026-03-31","named_holdings":17,"book_value_yen":35965000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}